Genetic determinants of Plasmodium vivax relapse

间日疟原虫复发的遗传决定因素

• 批准号: 8991706
• 负责人: Jessica Lin
• 金额: $ 16.63万
• 依托单位: UNIV OF NORTH CAROLINA CHAPEL HILL
• 依托单位国家: 美国
• 财政年份: 2014
• 资助国家: 美国
• 起止时间: 2014-02-01 至 2019-01-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8991706
• 关键词: Adverse drug effect; Africa; Award; Bioinformatics; Bite; Blood Circulation; Cambodian; Clinical; Clinical Research; Clinical Trials; Communicable Diseases; Complement; Culicidae; Data; Detection; Discipline; Disease; Educational workshop; Epidemiologic Studies; Epidemiology; Exhibits; Experimental Models; Foundations; Frequencies; Funding; Future; Genes; Genetic; Genetic Determinism; Genetic Polymorphism; Genomic Segment; Genomics; Genotype; Goals; Health; High-Throughput Nucleotide Sequencing; Human; Infection; Investigation; Lead; Light; Liver; Malaria; Master of Science; Mentors; Methods; Microsatellite Repeats; Minority; Molecular; Molecular Epidemiology; North Carolina; Parasites; Patients; Pattern; Persons; Physicians; Plasmodium vivax; Population; Population Genetics; Primaquine; Principal Component Analysis; Public Health; Recurrence; Regulator Genes; Relapse; Research; Research Design; Research Personnel; Research Training; Sampling; Schools; Scientist; Single Nucleotide Polymorphism; Southeastern Asia; Sporozoites; Staging; Statistical Models; Techniques; Technology; Therapeutic Intervention; Time; Training; Translating; Universities; Variant; Work; base; cohort; deep sequencing; design; drug relapse; experience; genetic analysis; genetic epidemiology; genetic signature; genetic variant; genome sequencing; genome wide association study; genome-wide; genomic tools; improved; next generation sequencing; professor; relapse prediction; skills; targeted treatment; therapeutic target; tool; transmission process; whole genome

DESCRIPTION (provided by applicant): In recent years, there has been an increased appreciation that global malaria elimination efforts cannot succeed without a better understanding of Plasmodium vivax, the most prevalent malaria species outside Africa. In particular, our poor understanding of P. vivax's ability to establish dormant hypnozoite stages that reactivate to cause periodic relapse is a major barrier to malaria elimination due to the lack of deployable anti-relapse therapy. This proposal will use new genomic technologies to achieve a better understanding of the genetic determinants of vivax relapse, with the ultimate goal of identifying targets for therapeutic intervention. Specifically, in light of limited experimental models of vivax, we will apply next generation sequencing techniques to clinical samples from vivax-infected Cambodian patients to provide the first detailed look at the genetic signatures of relapsing parasites. In Aim 1, we will use amplicon deep sequencing to characterize the in-host diversity of initial and recurrent vivax infections in this cohort. Results will be combined with microsatellite genotyping, population genetic analysis, and statistical modeling to distinguish relapses from re-infections and identify genetic variants predisposed to relapse. We will then whole genome sequence parasites causing relapsing vs. non-relapsing infection in Aim 2 to search for genetic polymorphisms associated with relapse. Our overall hypothesis is that frequently relapsing parasites contain polymorphisms in sporozoite (pre-hypnozoite) specific genes that increase hypnozoite formation and confer increased relapse potential. The candidate is an Assistant Professor in the Division of Infectious Diseases at the University of North Carolina. She has field experience in Southeast Asia, and has pursued clinical and molecular epidemiologic research in malaria for the past 5 years at UNC's Gillings School of Global Public Health. The proposed investigations will build on this foundation to equip her with new skills in genomics, bioinformatics, population genetics, and genetic epidemiology essential for conducting malaria genomics research. She will draw on her mentors' pioneering efforts in next generation sequencing of malaria as well as their respective expertise in malaria epidemiology, population genomics, and the application of these disciplines to public health. The Award will also provide protected time for her to attend didactic courses and hands-on workshops, and to finish a Master's of Science in Clinical Research that includes training in clinical study design. Combined with the preliminary data and tools developed via her research, this training will allow her to pursue R01 funding to conduct genome wide association studies of relapse using large vivax cohorts. The candidate's long-term goal is to become a leading vivax clinical scientist who combines sophisticated molecular tools with clinical studies to help achieve elimination of malaria. Her mentors and her division have a long track record in nurturing successful physician-scientists. They are committed to helping her achieve independence as a translational investigator devoted to understanding the genetic basis of vivax relapse.

描述（由申请人提供）：近年来，人们越来越认识到，如果不能更好地了解间日疟原虫（非洲以外最流行的疟疾物种），全球消除疟疾的努力就不可能成功。特别是，我们对间日疟原虫建立休眠催眠期的能力了解不足，催眠期会重新激活，导致周期性复发，这是消除疟疾的主要障碍